Molecular biology of chronic myeloid leukemia

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1601-1610

  Maru, Yoshiro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; PROTEIN TYROSINE KINASE;

CHRONIC MYELOID LEUKEMIA; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; HUMAN; LEUKEMIA CELL; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TUMOR MICROENVIRONMENT;

ANIMALS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84865776237     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02346.x     Document Type: Review

References (105)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-3.
2. de Klein A, van Kessel AG, Grosveld G et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765-7.
3. Heisterkamp N, Stephenson JR, Groffen J et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983; 306: 239-42.
4. Neviani P, Santhanam R, Trotta R et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-68.
5. Corbin AS, Agarwal A, Loriaux M et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
6. European School of Hematology (ESH). Eleventh International Conference Chronic Myeloid Leukaemia - Biological Basis of Therapy. September 11-13. Bordeaux, France, 2009.
7. Radich JP. Chronic myeloid leukemia 2010: where are we now and where can we go? Hematology Am Soc Hematol Educ Program 2010; 2010: 122-8.
8. Tsukahara F, Maru Y. Bag1 directly routes immature BCR-ABL for proteasomal degradation. Blood 2010; 116: 3582-92.
9. Rosenbaum JC, Fredrickson EK, Oeser ML et al. Disorder targets misorder in nuclear quality control degradation: a disordered ubiquitin ligase directly recognizes its misfolded substrates. Mol Cell 2011; 41: 93-106.
10. Laneuville P, Sun G, Timm M et al. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood 1992; 80: 1788-97.
11. Yan D, Kobayashi S, Yamin T et al. Leukemogenic fusion gene (p190 BCR-ABL) transduction into hematopoietic stem/progenitor cells the common marmoset. Open J Hematol Dis 2012; 2: 1-10.
12. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
13. Grebien F, Hantschel O, Wojcik J et al. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 2011; 147: 306-19.
14. Vajpai N, Strauss A, Fendrich G et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008; 283: 18292-302.
15. Chan WW, Wise SC, Kaufman MD et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011; 19: 556-68.
16. Nagar B, Hantschel O, Young MA et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003; 112: 859-71.
17. Nagar B, Hantschel O, Seeliger M et al. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 2006; 21: 787-98.
18. Zhang J, Adrian FJ, Jahnke W et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010; 463: 501-6.
19. Maru Y. Molecular biology of chronic myeloid leukemia. Int J Hematol 2001; 73: 308-22.
20. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831-43.
21. Zhao X, Ghaffari S, Lodish H et al. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol 2002; 9: 117-20.
22. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
23. Soisson SM, Nimnual AS, Uy M et al. Crystal structure of the Dbl and pleckstrin homology domains from the human Son of sevenless protein. Cell 1998; 95: 259-68.
24. Jamieson CH, Ailles LE, Dylla SJ et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-67.
25. Minami Y, Stuart SA, Ikawa T et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A 2008; 105: 17967-72.
26. Chung E, Hsu CL, Kondo M. Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder. PLoS One 2011; 6: e28350.
27. Sattler M, Verma S, Shrikhande G et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275: 24273-8.
28. Kin Y, Shibuya M, Maru Y. Inhibition of protein kinase C δ has negative effect on anchorage-independent growth of BCR-ABL-transformed Rat1 cells. Leuk Res 2001; 25: 821-5.
29. Jain SK, Langdon WY, Varticovski L. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase. Oncogene 1997; 14: 2217-28.
30. Kharas MG, Okabe R, Ganis JJ et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010; 115: 1406-15.
31. Hirayama A, Kami K, Sugimoto M et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009; 69: 4918-25.
32. Kim JH, Chu SC, Gramlich JL et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105: 1717-23.
33. Christofk HR, Vander Heiden MG, Wu N et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008; 452: 181-6.
34. Hitosugi T, Fan J, Chung TW et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell 2011; 44: 864-77.
35. Mayerhofer M, Valent P, Sperr WR et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767-75.
36. Lounnas N, Frelin C, Gonthier N et al. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int J Cancer 2009; 125: 308-17.
37. Dan HC, Cooper MJ, Cogswell PC et al. Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008; 22: 1490-500.
38. Krempler A, Qi Y, Triplett AA et al. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis 2004; 40: 52-7.
39. Deming PB, Schafer ZT, Tashker JS et al. Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. Mol Cell Biol 2004; 24: 10289-99.
40. Samanta A, Perazzona B, Chakraborty S et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 2011; 25: 463-72.
41. Jatiani SS, Cosenza SC, Reddy MV et al. Non-ATP-competitive dual inhibitor of JAK2 and BCR-ABL Kinases: elucidation of a novel therapeutic spectrum based on substrate competitive inhibition. Genes Cancer 2010; 4: 331-45.
42. Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer 2010; 1: 605-16.
43. Maru Y. Use of glutathione S-Transferase and break point cluster region protein as artificial dimerization domains to activate tyrosine kinases. Methods Enzymol 2000; 327: 429-40.
44. Radziwill G, Erdmann RA, Margelisch U et al. The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain. Mol Cell Biol 2003; 23: 4663-72.
45. Mishra S, Reichert A, Cunnick J et al. Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 2003; 22: 8255-62.
46. Sahay S, Pannucci NL, Mahon GM et al. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 2008; 27: 2064-71.
47. Kin Y, Li G, Shibuya M et al. The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome. J Biol Chem 2001; 276: 39462-8.
48. Mali RS, Ramdas B, Ma P et al. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell 2011; 20: 357-69.
49. Lu Z, Hunter T. Degradation of activated protein kinases by ubiquitination. Annu Rev Biochem 2009; 78: 435-75.
50. Kobayashi S, Sawano A, Nojima Y et al. The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1). FASEB J 2004; 18: 929-31.
51. Bauer S, Yu LK, Demetri GD et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006; 66: 9153-61.
52. Peng C, Brain J, Hu Y et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007; 110: 678-85.
53. Weigert O, Lane AA, Bird L et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012; 209: 259-73.
54. Wulf G, Finn G, Suizu F et al. Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat Cell Biol 2005; 7: 435-41.
55. Zhang Q, Tsukahara F, Maru Y. N-acetyl-cysteine enhances growth in BCR-ABL-transformed cells. Cancer Sci 2005; 96: 240-4.
56. Leu JI, Pimkina J, Frank A et al. A small molecule inhibitor of inducible heat shock protein 70. Mol Cell 2009; 36: 15-27.
57. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008; 14: 250-62.
58. Sillaber C, Mayerhofer M, Bohm A et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008; 38: 43-52.
59. Puissant A, Robert G, Fenouille N et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2010; 70: 1042-52.
60. Thorburn J, Horita H, Redzic J et al. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ 2009; 16: 175-83.
61. Bellodi C, Lidonnici MR, Hamilton A et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109-23.
62. Khan MM, Nomura T, Chiba T et al. The fusion oncoprotein PML-RARα induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress. J Biol Chem 2004; 279: 11814-24.
63. Podsypanina K, Du YC, Jechlinger M et al. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008; 321: 1841-4.
64. Joo JH, Dorsey FC, Joshi A et al. Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell 2011; 43: 572-85.
65. Zhang B, Strauss AC, Chu S et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010; 17: 427-42.
66. Takubo K, Goda N, Yamada W et al. Regulation of the HIF-1α level is essential for hematopoietic stem cells. Cell Stem Cell 2010; 7: 391-402.
67. Arai F, Hirao A, Ohmura M et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149-61.
68. Fiegl M, Samudio I, Clise-Dwyer K et al. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 2009; 113: 1504-12.
69. Zou P, Yoshihara H, Hosokawa K et al. p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell 2011; 9: 247-61.
70. Malanchi I, Santamaria-Martínez A, Susanto E et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011; 481: 85-9.
71. Coluccia AM, Vacca A, Dunach M et al. Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007; 26: 1456-66.
72. Maru Y. The tumor suppressor LZTS2 functions through the cellular samurai Katanin Cent. Eur J Biol 2009; 4: 1-10.
73. Bruns I, Czibere A, Fischer JC et al. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 2009; 23: 892-9.
74. Chang YC, Tien SC, Tien HF et al. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells. Oncogene 2009; 28: 4105-15.
75. Maru Y. Logical structures extracted from metastasis experiments. Cancer Sci 2009; 100: 2006-13.
76. Naka K, Hoshii T, Muraguchi T et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-80.
77. Kim S, Takahashi H, Lin WW et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-6.
78. Schmidt T, Kharabi Masouleh B, Loges S et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011; 19: 740-53.
79. Fischer C, Jonckx B, Mazzone M et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463-75.
80. Lu X, Mu E, Wei Y et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 2011; 20: 701-14.
81. Nagai Y, Garrett KP, Ohta S et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006; 24: 801-12.
82. Reynaud D, Pietras E, Barry-Holson K et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011; 20: 661-73.
83. Harris RE, Beebe-Donk J, Doss H et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 2005; 13: 559-83.
84. Kim MY, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-26.
85. Maru Y. A concept of homeostatic inflammation provided by endogenous TLR4 agonists that function before and after danger signal for metastasis. Antiinflamm Antiallergy Agents Med Chem 2009; 8: 337-47.
86. Vandenabeele P, Declercq W, Van Herreweghe F et al. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 2010; 3: re4.
87. Jelinek J, Gharibyan V, Estecio MR et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One 2011; 6: e22110.
88. O'Hare T, Zabriskie MS, Eide CA et al. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood 2011; 118: 5250-4.
89. Fabarius A, Giehl M, Frank O et al. Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 2005; 19: 1573-8.
90. Gleixner KV, Ferenc V, Peter Β. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 2010; 70: 1513-23.
91. Klemm L, Duy C, Iacobucci I et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009; 16: 232-45.
92. Crouch EE, Li Z, Takizawa M et al. Regulation of AID expression in the immune response. J Exp Med 2007; 204: 1145-56.
93. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 2011; 51: 1289-301.
94. Antoniou AN, Guiliano DB, Lenart I et al. The oxidative folding and misfolding of human leukocyte antigen-b27. Antioxid Redox Signal 2011; 15: 669-84.
95. Wang Y, Liu L, Pazhanisamy SK et al. Total body irradiation causes residual bone marrow injury by induction of persistent oxidative stress in murine hematopoietic stem cells. Free Radic Biol Med 2010; 48: 348-56.
96. Rodier F, Coppe JP, Patil CK et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009; 11: 973-9.
97. Riddell JR, Wang XY, Minderman H et al. Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4. J Immunol 2010; 184: 1022-30.
98. Valeri A, Alonso-Ferrero ME, Rio P et al. Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells. PLoS One 2010; 5: e15525.
99. Slupianek A, Dasgupta Y, Ren SY et al. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood 2011; 118: 1062-8.
100. Li G, Liu J, Abu-Asab M, Masabumi S et al. XPB induces C1D expression to counteract UV-induced apoptosis. Mol Cancer Res 2010; 8: 885-95.
101. Yanagida M. Clearing the way for mitosis: is cohesin a target? Nat Rev Mol Cell Biol 2009; 10: 489-96.
102. Chen X, Zhang J, Lee J et al. A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. Mol Cell 2006; 22: 489-99.
103. Dosztányi Z, Csizmok V, Tompa P et al. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 2005; 21: 3433-4.
104. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147: 728-41.
105. Pantuck AJ, An J, Liu H et al. NF-κB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Cancer Res 2010; 70: 752-61.